Dear customers,
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal https://eifu.r-biopharm.com.
R-Biopharm AG receives FDA clearance for RIDA®GENE Norovirus GI/GII, a real time RT-PCR assay for the detection and differentiation of norovirus genogroup I (GI) and II (GII)
RIDA®GENE 2.0
New: RIDA®GENE Parainfluenza
Human parainfluenza viruses (HPIV) can cause both upper respiratory infections and lower respiratory infections.
Reliable detection of novel influenza A variants with R-Biopharm RIDA®GENE test systems
Respiratory diseases often show similar symptoms, but are triggered by a variety of pathogens, such as viruses, bacteria and fungi. Rapid, comprehensive and reliable diagnostics as a basis for [...]
RIDA®GENE
Hospital aquired infections and drug resistance
PCR
Parasitology
Influenza season 2015 dominated by new influenza A variant (H3N2)
The RIDA®GENE real-time PCR assays for the detection of Influenza (RIDA®GENE Flu, RIDA®GENE Flu LC2.0, RIDA®GENE Flu & RSV) detect the currently circulating drift variant of influenza A (H3N2).